XML 45 R26.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Income Taxes | Income Taxes In August 2022, the U.S. Government enacted legislation commonly referred to as the Inflation Reduction Act that became effective January 1, 2023. The main provisions of the Inflation Reduction Act that impact us are: (i) a 15% corporate alternative minimum tax (“Corporate AMT”) and (ii) a 1% excise tax on share repurchases, which is recorded in equity on our consolidated statements of stockholders’ equity (deficit). We are considered an “applicable corporation” for purposes of Corporate AMT. We expect our regular federal income tax liability will generally exceed our Corporate AMT liability; however, certain unique circumstances may result in our Corporate AMT liability exceeding our regular federal income tax liability, including when tax losses are reported in a different year than book losses. Earnings (losses) before income taxes and provision (benefit) for income taxes consisted of the following:
| For the Years Ended December 31,
(in millions) | 2024 |  | 2023 |  | 2022
Earnings (losses) before income taxes: |  |  |  |  |
United States | $ | 13,680 |  |  | $ | 10,971 |  |  | $ | 7,628 |
Outside United States | (22) |  |  | (43) |  |  | (239) |
Total | $ | 13,658 |  |  | $ | 10,928 |  |  | $ | 7,389 |
Provision (benefit) for income taxes: |  |  |  |  |
Current: |  |  |  |  |
Federal | $ | 927 |  |  | $ | 2,346 |  |  | $ | 1,968 |
State and local | 516 |  |  | 681 |  |  | 603 |
Outside United States | — |  |  | 1 |  |  | 1 |
| 1,443 |  |  | 3,028 |  |  | 2,572 |
Deferred: |  |  |  |  |
Federal | 764 |  |  | (133) |  |  | (893) |
State and local | 187 |  |  | (97) |  |  | (54) |
| 951 |  |  | (230) |  |  | (947) |
Total provision for income taxes | $ | 2,394 |  |  | $ | 2,798 |  |  | $ | 1,625 |
Our U.S. subsidiaries join in the filing of a U.S. federal consolidated income tax return. The U.S. federal income tax statute of limitations remains open for the year 2017 and forward, with years 2017 through 2023 currently under examination by the Internal Revenue Service (“IRS”) as part of an audit conducted in the ordinary course of business. State statutes of limitations will also generally remain open for the year 2017 and forward. Certain of our state tax returns are currently under examination by various states as part of routine audits conducted in the ordinary course of business. A reconciliation of the beginning and ending unrecognized tax benefits was as follows:
| For the Years Ended December 31,
(in millions) | 2024 |  | 2023 |  | 2022
Balance at beginning of year | $ | 1,608 |  |  | $ | 69 |  |  | $ | 53 |
Additions based on tax positions related to the current year | — |  |  | 1,548 |  |  | 1 |
Additions for tax positions of prior years | 33 |  |  | — |  |  | 16 |
Reductions for tax positions related to IRS Agreement | (1,343) |  |  | — |  |  | — |
Reductions for tax positions of prior years | (16) |  |  | (6) |  |  | — |
Tax settlements | — |  |  | (3) |  |  | (1) |
Balance at end of year | $ | 282 |  |  | $ | 1,608 |  |  | $ | 69 |
The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at December 31, 2024, was $189 million, along with $27 million affecting deferred taxes. The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at December 31, 2023, was $35 million, along with $1,573 million affecting deferred taxes, a portion of which would also impact the effective tax rate due to the release of a valuation allowance, as discussed below. In October 2024, we entered into an agreement with the IRS (“IRS Agreement”) regarding the tax treatment of a $6.4 billion ordinary loss we recognized in 2023 for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL. In 2023, we fully reserved for the tax benefit associated with this ordinary loss by recording an unrecognized tax benefit of $1,548 million. There was no impact to our consolidated statement of earnings for the year ended December 31, 2023. In addition, the $1,548 million increase in unrecognized tax benefits was partially offset by $428 million associated with an indirect deferred tax benefit caused by our estimated Corporate AMT credit carryforward. Consistent with the terms of the IRS Agreement, we claimed a $4.0 billion ordinary loss and a $2.4 billion capital loss on our 2023 tax return. For the year ended December 31, 2024, we recorded a tax benefit of $887 million due to the reversal of the unrecognized tax benefit in our consolidated statement of earnings, resulting in the partial release of a valuation allowance against our JUUL-related losses as discussed below. The reversals of the unrecognized tax benefit and indirect deferred tax benefit caused by our estimated Corporate AMT credit carryforward in 2023 resulted in a net decrease of $1,120 million in other liabilities on our consolidated balance sheet at December 31, 2024. At December 31, 2024, 2023 and 2022, the amount of accrued interest and penalties on our consolidated balance sheets was $18 million, $36 million and $18 million, respectively. For the years ended December 31, 2024, 2023 and 2022, we recognized in our consolidated statements of earnings $(24) million, $20 million and $8 million, respectively, of gross interest (income) expense and penalties associated with uncertain tax positions. We recognize accrued interest and penalties associated with uncertain tax positions as part of the tax provision. We are subject to income taxation in many jurisdictions. Unrecognized tax benefits reflect the differences between tax positions we have taken or expect to take on income tax returns and the amounts recognized in our financial statements. Resolution of the related tax positions with the relevant tax authorities may take many years to complete, and such timing is not entirely within our control. It is reasonably possible that within the next 12 months certain examinations will be resolved, which could result in a decrease in unrecognized tax benefits of approximately $1 million. A reconciliation between actual income taxes and amounts computed by applying the federal statutory rate to earnings before income taxes was as follows:
|  | For the Years Ended December 31,
|  | 2024 |  | 2023 |  | 2022
(dollars in millions) |  | $ |  | % |  | $ |  | % |  | $ |  | %
U.S. federal statutory rate |  | $ | 2,868 |  |  | 21.0 | % |  | $ | 2,295 |  |  | 21.0 | % |  | $ | 1,552 |  |  | 21.0 | %
Increase (decrease) resulting from: |  |  |  |  |  |  |  |  |  |  |  |
State and local income taxes, net of federal tax benefit |  | 557 |  |  | 4.1 |  |  | 463 |  |  | 4.2 |  |  | 435 |  |  | 5.9 |
Tax basis in foreign investments |  | (11) |  |  | (0.1) |  |  | 34 |  |  | 0.3 |  |  | 11 |  |  | 0.1 |
Uncertain tax positions |  | (15) |  |  | (0.1) |  |  | 8 |  |  | 0.1 |  |  | — |  |  | — |
Investment in ABI |  | (35) |  |  | (0.3) |  |  | (37) |  |  | (0.3) |  |  | (24) |  |  | (0.3) |
Investment in JUUL |  | — |  |  | — |  |  | 53 |  |  | 0.5 |  |  | 306 |  |  | 4.1 |
Investment in Cronos |  | 3 |  |  | — |  |  | 11 |  |  | 0.1 |  |  | 30 |  |  | 0.4 |
Valuation allowance releases |  | (939) |  |  | (6.9) |  |  | — |  |  | — |  |  | (664) |  |  | (9.0) |
Other |  | (34) |  |  | (0.2) |  |  | (29) |  |  | (0.3) |  |  | (21) |  |  | (0.2) |
Effective tax rate |  | $ | 2,394 |  |  | 17.5 | % |  | $ | 2,798 |  |  | 25.6 | % |  | $ | 1,625 |  |  | 22.0 | %
The tax provision in 2024 included tax benefits of $939 million due primarily to the release of valuation allowances recorded against a deferred tax asset related to our JUUL-related losses as a result of the IRS Agreement and the ABI Transaction, partially offset by state tax expense, net of federal benefit, of $557 million. The tax provision in 2023 included state tax expense, net of federal benefit, of $463 million and tax expense of $53 million for a valuation allowance recorded against a deferred tax asset related to the disposition of our former investment in JUUL. The tax provision in 2022 included tax benefits of $664 million due primarily to the release of valuation allowances related to the anticipated ability to utilize a portion of existing capital losses. These tax benefits were partially offset by tax expense of $306 million for a valuation allowance recorded against a deferred tax asset related to the decreases in the estimated fair value of our former investment in JUUL and by the state tax treatment of the impairment charge on our investment in ABI. The tax effects of temporary differences that gave rise to deferred income tax assets and liabilities consisted of the following at December 31:
(in millions) | 2024 |  | 2023
Deferred income tax assets: |  |  |
Accrued postretirement and postemployment benefits | $ | 270 |  |  | $ | 302 |
Settlement charges | 585 |  |  | 644 |
JUUL-related losses | 207 |  |  | 2,028 |
Investment in Cronos | 404 |  |  | 397 |
IQOS deferred gain | — |  |  | 691 |
Research and development costs | 112 |  |  | 86 |
Net operating losses and tax credit carryforwards | 224 |  |  | 217 |
Other | — |  |  | 39 |
Total deferred income tax assets | 1,802 |  |  | 4,404 |
Deferred income tax liabilities: |  |  |
Property, plant and equipment | (235) |  |  | (237) |
Intangible assets | (3,032) |  |  | (3,210) |
Investment in ABI | (1,370) |  |  | (1,391) |
Accrued pension costs | (108) |  |  | (81) |
Other | (133) |  |  | — |
Total deferred income tax liabilities | (4,878) |  |  | (4,919) |
Valuation allowances | (668) |  |  | (2,256) |
Net deferred income tax liabilities | $ | (3,744) |  |  | $ | (2,771) |
At December 31, 2024, we had JUUL-related gross capital loss carryforwards of $1.0 billion available to offset capital gains through 2028. We had estimated gross federal, state and foreign tax net operating losses (“NOLs”) of $374 million, $1,066 million and $38 million, respectively. The federal NOLs, a majority of the state NOLs and the foreign NOLs have indefinite carryforward periods. After giving effect to the IRS Agreement and $1.7 billion of JUUL-related capital losses previously utilized against capital gains related to the IQOS Transaction, we have $5.7 billion (which includes a $3.5 billion outside basis difference in a domestic subsidiary, a $1.2 billion outside basis difference in a foreign subsidiary and $1.0 billion of capital loss carryforwards) of the $12.8 billion tax loss related to our former investment in JUUL remaining to offset future potential capital gains. For financial statement purposes, none of the tax benefit for the remaining $5.7 billion was recognized at December 31, 2024. A reconciliation of the beginning and ending valuation allowances was as follows:
|  | For the Years Ended December 31,
(in millions) |  | 2024 |  | 2023 |  | 2022
Balance at beginning of year |  | $ | 2,256 |  |  | $ | 2,800 |  |  | $ | 3,097 |
Additions to valuation allowance charged to income tax expense |  | 244 |  |  | 114 |  |  | 429 |
Reductions to valuation allowance credited to income tax benefit |  | (1,337) |  |  | (6) |  |  | (730) |
(Reductions) additions to valuation allowance due to NJOY Transaction (no impact to earnings) |  | (4) |  |  | 12 |  |  | — |
Reductions to valuation allowance offset to deferred tax asset (no impact to earnings) |  | (491) |  |  | (663) |  |  | — |
Foreign currency translation |  | — |  |  | (1) |  |  | 4 |
Balance at end of year |  | $ | 668 |  |  | $ | 2,256 |  |  | $ | 2,800 |
We determine deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when it is more likely than not that some portion or all of a deferred tax asset will not be realized. We determine the realizability of deferred tax assets based on the weight of all available positive and negative evidence. In reaching this determination, we consider the character of the assets and the possible sources of taxable income of the appropriate character within the available carryback and carryforward periods available under the tax law. As has occurred in prior periods, there is a potential that sufficient positive evidence may be available in future periods to cause us to reduce or eliminate the valuation allowance on certain deferred tax assets. That change to the valuation allowance would result in the recognition of previously unrecognized deferred tax assets and a decrease in income tax expense in the period the release is recorded. The additions to valuation allowances during 2024 were due primarily to deferred tax assets recorded in connection with our JUUL-related capital loss carryforwards. The reductions to valuation allowances during 2024 were due primarily to the $4.0 billion of ordinary losses recognized as part of the IRS Agreement, the reduction of a deferred tax asset for the portion of our JUUL-related capital losses that is now part of our tax basis in the shares of a domestic subsidiary and the ABI Transaction. This outside basis difference of the domestic subsidiary is not recognized as a deferred tax asset since we do not expect the temporary difference to reverse in the foreseeable future. The cumulative valuation allowance at December 31, 2024 was primarily attributable to deferred tax assets recorded in connection with our investment in Cronos ($402 million) and our JUUL-related capital loss carryforwards ($207 million). The additions to valuation allowances during 2023 were due primarily to deferred tax assets recorded in connection with our former investment in JUUL. The reductions to valuation allowances during 2023 were due primarily to the reduction of a deferred tax asset for the portion of our JUUL capital losses that is now part of our tax basis in the shares of a foreign subsidiary. This outside basis difference of the foreign subsidiary is not recognized as a deferred tax asset since we do not expect the temporary difference to reverse in the foreseeable future. The cumulative valuation allowance at December 31, 2023 was primarily attributable to deferred tax assets recorded in connection with our tax basis in the shares of a domestic subsidiary ($1,808 million) and our investment in Cronos ($397 million). The additions to valuation allowances during 2022 were due primarily to deferred tax assets recorded in connection with decreases in the estimated fair value of our former investment in JUUL. The reductions to valuation allowances during 2022 were due primarily to the anticipated ability to utilize a portion of existing losses related to our former investment in JUUL and the abandonment of our Cronos warrant. The cumulative valuation allowance at December 31, 2022 was primarily attributable to deferred tax assets recorded in connection with our former investment in JUUL ($2,394 million) and our investment in Cronos ($379 million). For a discussion regarding our former investment in JUUL and current investments in ABI and Cronos, see Note 8. Investments in Equity Securities.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration